March 10, 2026
Sandoz bets on its own new biosimilar unit with a veteran hire
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
Pharmaceuticals, Biotechnology and Life Sciences
Tag: biosimilars
April 15, 2019
United States Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “US Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025” report has been added to ResearchAndMarkets.com’s offering. “US…
January 19, 2018
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company,…
October 27, 2017
Sandoz is seeking approval for use of its biosimilar to Amgen’s Neulasta, EMA to take a look at it
Novartis division Sandoz has gotten acceptance for its biosimilar to Amgen’s Neulasta by the European Medicines Agency (EMA) for regulatory…
September 12, 2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
May 31, 2017
Asia to be drug delivery technology market fastest-growing region
Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.
February 14, 2017
Global biosimilars market could see high double digit growth by 2022.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
April 8, 2016
Biosimilars: More Treatment Options Are on the Way
As the medical market grows, the US Food and Drug Administration FDA has published a neat piece about biosimilars. Recently, FDA has approved a second biosimilar product—Inflectra (Infliximab-dyyb), a biosimilar to Remicade (infliximab)—and expects to approve other biosimilars in the future.